PLRX Stock Price, Pliant Therapeutics Inc Quote, Chart

Market Summary

USD13.79-0.02

Delayedas of 13 May 2024, 03:03 pm

-0.14%

PLRX Stock Price

View Fullscreen

PLRX RSI Chart

PLRX Valuation

Market Cap

833.1M

Price/Earnings (Trailing)

-4.88

Price/Sales (Trailing)

527.28

Price/Free Cashflow

-7.02

PLRX Price/Sales (Trailing)

PLRX Profitability

Return on Equity

-39.04%

Return on Assets

-32.73%

Free Cashflow Yield

-14.24%

PLRX Fundamentals

PLRX Revenue

Revenue (TTM)

1.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

PLRX Earnings

Earnings (TTM)

-170.7M

Earnings Growth (Yr)

-25.05%

Earnings Growth (Qtr)

-14.22%

Breaking Down PLRX Revenue

52 Week Range

13.5924.74

(Low)(High)

Last 7 days

4.2%

Last 30 days

-7.4%

Last 90 days

-18.4%

Trailing 12 Months

-40.0%

How does PLRX drawdown profile look like?

PLRX Financial Health

Current Ratio

16.12

Debt/Equity

0.07

Debt/Cashflow

-3.88

PLRX Investor Care

Shares Dilution (1Y)

1.98%

Diluted EPS (TTM)

-2.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	9.8M	5.0M	3.5M	1.6M
2022	6.6M	9.8M	9.7M	9.7M
2021	15.1M	13.2M	10.0M	7.6M
2020	53.2M	49.4M	45.6M	41.8M
2019	0	0	0	57.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pliant Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	cummings keith lamont	acquired	43,680	2.08	21,000	chief financial officer
Jan 23, 2024	cummings keith lamont	acquired	-	-	55,250	chief financial officer
Jan 23, 2024	coulie bernard	acquired	-	-	128,150	president and ceo
Jan 23, 2024	ouimette mike	acquired	-	-	31,500	general counsel & corp. sec'y
Jan 23, 2024	lefebvre eric	acquired	-	-	42,900	chief medical officer
Jan 23, 2024	hull hans	acquired	-	-	31,500	chief business officer
Jan 23, 2024	cheung lily	acquired	-	-	26,000	chief human resource officer
Jan 17, 2024	hull hans	sold	-168,613	17.23	-9,786	chief business officer
Jan 17, 2024	ouimette mike	sold	-89,544	17.23	-5,197	general counsel & corp. sec'y
Jan 17, 2024	cummings keith lamont	sold	-168,527	17.23	-9,781	chief financial officer

Which funds bought or sold PLRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	VANGUARD GROUP INC	added	13.45	-3,695,400	51,827,500	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-85.34	-35,524	4,871	-%
May 10, 2024	BlackRock Inc.	reduced	-3.04	-17,590,200	69,365,200	-%
May 10, 2024	CITIGROUP INC	added	198	1,883,830	3,178,240	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	3.15	-189,554	1,063,120	-%
May 10, 2024	GROUP ONE TRADING, L.P.	reduced	-8.02	-56,806	176,759	-%
May 10, 2024	CREDIT SUISSE AG/	added	5.08	-151,811	968,872	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	3,267	25,637	26,597	-%
May 10, 2024	Covestor Ltd	unchanged	-	-	-	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	94.82	1,682,290	4,472,530	-%

Are Funds Buying or Selling PLRX?

Are funds buying PLRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PLRX

No. of Funds

Unveiling Pliant Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	blue owl capital holdings lp	5.02%	3,004,199	SC 13G
Feb 14, 2024	price t rowe associates inc /md/	6.3%	3,788,116	SC 13G
Feb 14, 2024	deep track capital, lp	9.60%	5,750,000	SC 13G/A
Feb 14, 2024	first light asset management, llc	6.07%	3,634,510	SC 13G
Feb 14, 2024	third rock ventures iii, l.p.	0.6%	339,160	SC 13G/A
Feb 14, 2024	redmile group, llc	4.5%	2,696,648	SC 13G/A
Feb 13, 2024	vanguard group inc	5.12%	3,065,869	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	laurion capital management lp	5.98%	3,583,567	SC 13G
Jan 25, 2024	blackrock inc.	8.0%	4,801,517	SC 13G

Recent SEC filings of Pliant Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	4	Insider Trading
May 06, 2024	8-K	Current Report
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Mar 12, 2024	8-K	Current Report
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	8-K	Current Report
Feb 27, 2024	S-8	Employee Benefits Plan
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Pliant Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.94%	-6.22%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	-2.91%	-28.25%	-57.66	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.16%	-14.11%	75.52	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.25%	-16.30%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.06%	107.74%	-9.96	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-22.86%	-53.47%	-12.21	9.72	394.93%	39.61%
AXSM	3.4B	251.0M	1.43%	-8.15%	-11.62	13.72	73.58%	-86.73%
ARWR	2.7B	240.7M	-5.83%	-38.95%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.20%	-29.75%	-1.5K	3.1	56.43%	98.83%
SMALL-CAP
CPRX	1.8B	411.3M	-0.89%	-10.62%	28.39	4.49	60.38%	-34.49%
NVAX	627.6M	996.6M	1.13%	-50.28%	-1.57	0.63	-26.66%	65.49%
CRBP	467.4M	881.7K	16.73%	369.82%	-13.85	481.06	-77.61%	33.36%
INO	261.3M	4.9M	-3.87%	15.02%	-1.93	53.69	-54.97%	51.71%
IBIO	6.6M	2.1M	-13.36%	77.36%	-0.24	2.14	-13.45%	66.37%

Pliant Therapeutics Inc News

Latest updates

Pliant Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-	-	-	-	248	1,332	1,965	1,482	4,989	1,249	1,999	1,610	1,789	2,174	4,465	4,814	3,600	28,938	-
Operating Expenses	11.4%	52,392	47,037	47,685	47,576	43,427	39,365	33,429	34,631	29,460	26,598	28,723	24,693	25,093	23,481	21,475	20,576	17,930	-
S&GA Expenses	-100.0%	-	13,854	15,346	14,574	14,154	14,251	8,823	8,296	8,579	7,846	7,671	5,475	6,566	5,627	4,591	3,040	4,011	-
R&D Expenses	11.9%	37,146	33,183	32,339	33,002	29,273	25,114	24,606	26,335	20,881	18,752	21,052	19,218	18,527	17,854	16,884	17,536	13,919	-
Interest Expenses	56.3%	501	321	317	319	311	317	301	173	-	-	-	-	-	-	-	-	-	-
Net Income	-14.2%	-46,955	-41,109	-41,487	-41,192	-37,548	-35,060	-30,615	-29,546	-28,100	-24,531	-27,045	-22,831	-22,856	-19,027	-16,534	-17,001	11,029	42,169
Net Income Margin	-5.8%	-108.07*	-102.11*	-43.80*	-28.73*	-13.59*	-12.73*	-11.61*	-11.09*	-15.42*	-12.85*	-9.14*	-6.14*	-	-	-	-	-	-
Free Cashflow	-26.2%	-31,763	-25,163	-36,318	-25,362	-30,439	-31,405	-19,194	-24,650	-21,142	-20,457	-22,990	-20,042	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	1.8%	522	512	540	575	598	351	377	185	197	221	234	256	275	296	312	329	119
Current Assets	-3.1%	490	506	534	566	588	340	366	174	185	209	229	251	271	291	308	324	112
Cash Equivalents	83.1%	116	63.00	58.00	55.00	103	34.00	45.00	25.00	33.00	52.00	45.00	35.00	51.00	51.00	55.00	178	86.00
Net PPE	57.1%	6.00	4.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	118.4%	84.00	39.00	37.00	42.00	36.00	37.00	40.00	37.00	23.00	22.00	14.00	12.00	11.00	12.00	12.00	13.00	9.00
Current Liabilities	6.5%	30.00	29.00	27.00	30.00	23.00	24.00	26.00	23.00	18.00	17.00	13.00	11.00	10.00	12.00	11.00	12.00	8.00
Long Term Debt	198.4%	30.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-7.7%	437	474	503	533	562	313	337	148	174	199	220	244	264	283	300	316	-
Retained Earnings	-9.4%	-546	-499	-458	-417	-375	-338	-303	-272	-243	-215	-190	-163	-140	-117	-98.80	-82.27	-76.29
Additional Paid-In Capital	1.2%	985	973	964	952	939	654	643	422	418	414	411	408	405	401	399	398	-
Shares Outstanding	0.7%	60.00	60.00	60.00	59.00	59.00	49.00	40.00	36.00	36.00	36.00	36.00	36.00	-	-	-	-	-
Float	-	-	-	-	1,008	-	-	-	282	-	-	-	752	-	-	-	856	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	-20.6%	-30,271	-25,102	-36,224	-24,759	-30,276	-31,239	-18,498	-24,396	-20,498	-19,865	-22,510	-19,403	-13,665	-16,485	-15,792	7,772	-12,766	-	-	-
Share Based Compensation	5.6%	9,666	9,152	10,362	13,046	11,923	10,855	4,809	3,403	3,531	2,768	2,811	2,280	2,578	1,515	1,169	786	425	-	-	-
Cashflow From Investing	86.5%	59,546	31,921	38,253	-22,978	-174,208	20,022	-178,252	6,495	1,531	25,783	32,100	3,584	12,232	11,906	-105,080	-106,319	-11,373	-	-	-
Cashflow From Financing	9848.9%	21,788	219	699	161	273,326	284	216,297	10,426	-153	516	449	192	1,370	237	-2,365	163,640	51,700	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PLRX Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 1,332
Operating expenses:
Research and development	(37,146)	(29,273)
General and administrative	(15,246)	(14,154)
Total operating expenses	(52,392)	(43,427)
Loss from operations	(52,392)	(42,095)
Interest and other income (expense), net	5,882	4,858
Interest expense	(445)	(311)
Net loss	$ (46,955)	$ (37,548)
Earnings Per Share [Abstract]
Basic (USD per share)	$ (0.78)	$ (0.67)
Diluted (USD per share)	$ (0.78)	$ (0.67)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Shares used in computing net loss per share - basic (in shares)	60,180,921	56,057,603
Shares used in computing net loss per share - diluted (in shares)	60,180,921	56,057,603
Comprehensive loss:
Net loss	$ (46,955)	$ (37,548)
Net unrealized (loss) gain on short-term investments	(834)	627
Total other comprehensive (loss) gain	(834)	627
Comprehensive loss	$ (47,789)	$ (36,921)

PLRX Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

^[1]

Current assets

Cash and cash equivalents

$ 114,297

$ 63,234

Short-term investments

368,092

431,011

Prepaid expenses and other current assets (Note 5)

7,509

11,257

Total current assets

489,898

505,502

Property and equipment, net

5,605

3,567

Operating lease right-of-use assets (Note 14)

24,228

1,211

Restricted cash

1,482

Other non-current assets

392

Total assets

521,605

512,154

Current liabilities

Accounts payable

7,327

4,531

Accrued research and development

16,423

12,456

Accrued liabilities (Note 6)

5,868

10,219

Operating lease liabilities, current (Note 14)

773

1,318

Total current liabilities

30,391

28,524

Operating lease liabilities, non-current (Note 14)

23,880

0

Long-term debt (Note 7)

30,002

10,054

Total liabilities

84,273

38,578

Commitments and Contingencies (Note 13)

Stockholders’ equity

Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, and none issued or outstanding at March 31, 2024 and December 31, 2023 (Note 9)

0

Common stock, $0.0001 par value per share; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; and 60,318,542 and 59,921,002 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively; (Note 10)

6

Additional paid-in capital

984,518

972,973

Accumulated deficit

(546,703)

(499,748)

Accumulated other comprehensive (loss) gain

(489)

345

Total stockholders’ equity

437,332

473,576

Total liabilities and stockholders’ equity

$ 521,605

$ 512,154

[1]	The condensed balance sheet as of December 31, 2023 has been derived from the audited financial statements as of that date.

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avÃƒÅ¸6 and avÃƒÅ¸1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avÃƒÅ¸1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avÃƒÅ¸8 and avÃƒÅ¸1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

CEO	Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.
WEBSITE	https://pliantrx.com
INDUSTRY	Biotechnology
EMPLOYEES	155

Pliant Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Pliant Therapeutics Inc? What does PLRX stand for in stocks?

PLRX is the stock ticker symbol of Pliant Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pliant Therapeutics Inc (PLRX)?

As of Fri May 10 2024, market cap of Pliant Therapeutics Inc is 833.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLRX stock?

You can check PLRX's fair value in chart for subscribers.

What is the fair value of PLRX stock?

You can check PLRX's fair value in chart for subscribers. The fair value of Pliant Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pliant Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PLRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pliant Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PLRX is over valued or under valued. Whether Pliant Therapeutics Inc is cheap or expensive depends on the assumptions which impact Pliant Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLRX.

What is Pliant Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 10 2024, PLRX's PE ratio (Price to Earnings) is -4.88 and Price to Sales (PS) ratio is 527.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLRX PE ratio will change depending on the future growth rate expectations of investors.